Update date
31 Dec 2023
Shareable Research Card
INDV - Indivior Pharmaceuticals, Inc. Noncurrent Liabilities
This metric view shows INDV - Indivior Pharmaceuticals, Inc. noncurrent liabilities history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2023
- Latest reported value
- $649,000,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2023
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2023.
- Latest reported value on this page: $649,000,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Noncurrent Liabilities
Latest reported noncurrent liabilities: $649,000,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2023
SEC-backed company facts were refreshed from filings filed on 03 Aug 2026.
Benchmark Context
How Noncurrent Liabilities compares with peers
Indivior Pharmaceuticals, Inc. sits in the top quarter of the current noncurrent liabilities sample.
Compared with
Compared with 25 companies reporting noncurrent liabilities in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 98.4x the current sample midpoint. Noncurrent Liabilities is down about 7.2% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2017 to 30 Sep 2025.
- Nearby companies in this sample: Orion S.A. and SIFY TECHNOLOGIES LTD.
- Current sample position: rank #5 of 25 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Indivior Pharmaceuticals, Inc.: Noncurrent Liabilities
Latest period: Q4 2023. Period end: 31 Dec 2023. Units: USD. Frequency: quarterly.
Noncurrent Liabilities is reported in company XBRL facts filed with the SEC.
Metric snapshot
- Latest value
- $649,000,000
- Coverage range
- 31 Dec 2021 - 31 Dec 2023
- Fact rows
- 3
What this metric tells you
- Shows reported noncurrent liabilities over 31 Dec 2021 - 31 Dec 2023.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 3 SEC fact rows for this metric and issuer.
How to read this chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC source
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Noncurrent Liabilities levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Indivior Pharmaceuticals, Inc. appears at rank #5 in the latest comparison sample.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | CRH PUBLIC LTD CO (crh) | $13,962,000,000 | Instant - 31 Dec 2022 | Open CRH PUBLIC LTD CO Noncurrent Liabilities |
| 2 | Flutter Entertainment plc (flut) | $5,605,445,000 | Instant - 31 Dec 2019 | Open Flutter Entertainment plc Noncurrent Liabilities |
| 3 | Diversified Energy Co (dec) | $4,028,738,000 | Instant - 30 Jun 2025 | Open Diversified Energy Co Noncurrent Liabilities |
| 4 | Orion S.A. (oec) | $767,972,000 | Instant - 30 Sep 2018 | Open Orion S.A. Noncurrent Liabilities |
| 5 | Indivior Pharmaceuticals, Inc. (indv) | $649,000,000 | Instant - 31 Dec 2023 | Open Indivior Pharmaceuticals, Inc. Noncurrent Liabilities |
| 6 | SIFY TECHNOLOGIES LTD (sify) | $413,461,000 | Instant - 31 Mar 2025 | Open SIFY TECHNOLOGIES LTD Noncurrent Liabilities |
Metric Details
- Metric
- Noncurrent Liabilities (NoncurrentLiabilities)
- Frequency coverage
-
quarterly
Comparability: Compare annual with annual and quarterly with quarterly
- Taxonomy
- ifrs-full
- Units tracked
- USD
- History range
-
31 Dec 2021 - 31 Dec 2023
Freshness: From parsed SEC XBRL facts on this page
- Facts on this page
-
3
Source: SEC company facts API
- SEC metric endpoint
- Open SEC company concept
Metric identity
Names, identifiers, and filing context for this profile.
1 identity field
Metric coverage
3 source fields
Source evidence
Original filing metadata and source links for verification.
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Noncurrent Liabilities, Quarterly (USD)
Noncurrent Liabilities, YoY Quarterly Change (%)
Indivior Pharmaceuticals, Inc. Quarterly Noncurrent Liabilities (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2023 | $649,000,000 | -$50,000,000 | -7.2% | 31 Dec 2023 | 20-F | 06 Mar 2024 | 2023 | FY |
| Q4 2022 | $699,000,000 | -$126,000,000 | -15% | 31 Dec 2022 | 20-F | 06 Mar 2024 | 2023 | FY |
| Q4 2021 | $825,000,000 | 31 Dec 2021 | 20-F | 06 Mar 2024 | 2023 | FY |
* marks a reported value that did not pass the local value check.